RxDoctor Payments Data

Robert McConville, MD

Family Medicine · Sanford, NCNPI 1104820133

Payments from drug & device makers

$13,566in general payments, 2019–2025

Across 822 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$1K
  • Lilly USA, LLC$923
  • AstraZeneca$812
  • Pfizer$800
  • Boehringer Ingelheim$548
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,39799%
  • Education$1691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk176$2,868
AbbVie(2 entities)80$1,152
Lilly USA, LLC61$923
AstraZeneca50$812
Pfizer52$800
Boehringer Ingelheim30$548
Merck35$521
Sanofi-aventis U.S. LLC34$510
Amgen35$470
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$425
Abbott18$330
Astellas Pharma US Inc14$312
Bayer16$297
Ardelyx, Inc.14$294
Amarin Pharma, Inc.16$267
Sumitomo Pharma America, Inc.10$220
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$194
Johnson & Johnson(2 entities)14$182
Corcept Therapeutics6$181
Exact Sciences9$165
Otsuka America Pharmaceutical, Inc.7$156
GSK8$149
Mylan Specialty L.p.7$147
Sunovion Pharmaceuticals Inc.8$122
Novartis7$102
Esperion Therapeutics, Inc.5$86
Biohaven Pharmaceuticals, Inc.6$84
Nestle Healthcare Nutrition Inc.4$78
Takeda Pharmaceuticals U.S.A., Inc.4$76
Insulet Corporation3$75
E.r. Squibb & Sons, L.L.C.4$75
Grifols USA, LLC3$69
Phathom Pharmaceuticals, Inc.4$67
Daiichi Sankyo Inc.3$61
Tolmar, Inc.2$50
Kowa Pharmaceuticals America, Inc.3$38
Antares Pharma, Inc.2$38
Vanda Pharmaceuticals Inc.2$37
Shield Therapeutics Inc1$36
Neos Therapeutics, LP3$35
Almatica Pharma LLC2$34
Dexcom, Inc.2$32
Shire North American Group Inc2$31
Organogenesis Inc.1$29
Xeris Pharmaceuticals, Inc.2$28
Boston Scientific1$25
Teva Pharmaceuticals USA, Inc.2$23
UCB, Inc.1$22
Lifescan, Inc.1$21
Aimmune Therapeutics, Inc.1$21
Biohaven Pharmaceutical Holding Company Ltd.1$20
The Binding Site Inc.1$19
Genentech USA, Inc.1$18
Ironwood Pharmaceuticals, Inc1$18
Avanir Pharmaceuticals, Inc.1$17
Inspire Medical Systems, Inc.1$16
Aytu Biopharma, Inc.1$16
Idorsia Pharmaceuticals US Inc1$16
Exeltis, USA Inc.1$15
Medtronic1$15

How this compares

$13,566 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,154
Medicare patients
136
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide229$260,843
JardianceEmpagliflozin227$198,434
EliquisApixaban184$162,425
Tresiba Flextouch U-200Insulin Degludec93$79,080
XareltoRivaroxaban103$77,415
MyrbetriqMirabegron89$64,701
FarxigaDapagliflozin Propanediol88$62,452
TrulicityDulaglutide28$45,150
OxycontinOxycodone Hcl40$44,917
MounjaroTirzepatide32$43,733
LinzessLinaclotide69$42,249
JanuviaSitagliptin Phosphate28$40,137
ZenpepLipase/Protease/Amylase13$38,826
RybelsusSemaglutide32$38,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$31,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$2,868$322,409272 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr$548$246,903294 claims
PfizerEliquis, Nurtec Odt$800$182,109196 claims
Lilly USA, LLCTrulicity, Mounjaro$923$88,88360 claims
Johnson & JohnsonXarelto$182$77,415103 claims
AstraZenecaFarxiga, Breztri Aerosphere$812$73,933106 claims
MerckJanuvia, Janumet Xr, Janumet$521$66,55859 claims
Astellas Pharma US IncMyrbetriq$312$64,70189 claims
AbbVieLinzess, Namzaric, Synthroid$1,152$58,120158 claims
GSKTrelegy Ellipta, Anoro Ellipta$149$44,42459 claims
Aimmune Therapeutics, Inc.Zenpep$21$38,82613 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$510$28,12816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Sanford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →